Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/99640
Title: Major Challenges in clinical management of TB/HIV coinfected patients in Eastern Europe compared with Western Europe and Latin America
Author: Efsen, Anne Marie W.
Schultze, Anna
Post, Frank A.
Panteleev, Alexander
Furrer, H.
Miller, Robert F.
Losso, Marcelo H.
Toibaro, Javier
Skrahin, Aliaksandr
Miró Meda, José M.
Caylà i Buqueras, Joan A.
Girardi, Enrico
Bruyand, Mathias
Obel, Niels
Podlekareva, Daria N.
Lundgren, Jens D.
Mocroft, Amanda
Kirk, Ole
Alcaide Fernández de Vega, Fernando
TB:HIV Study Group
Keywords: Tuberculosi
VIH (Virus)
Infeccions per VIH
Resistència als medicaments
Terapèutica
Europa de l'Est
Europa Occidental
Amèrica Llatina
Tuberculosis
HIV (Viruses)
HIV infections
Drug resistance
Therapeutics
Eastern Europe
Western Europe
Latin America
Issue Date: 30-Dec-2015
Publisher: Public Library of Science (PLoS)
Abstract: Objectives: rates of TB/HIV coinfection and multi-drug resistant (MDR)-TB are increasing in Eastern Europe (EE). We aimed to study clinical characteristics, factors associated with MDR-TB and predicted activity of empiric anti-TB treatment at time of TB diagnosis among TB/HIV coinfected patients in EE, Western Europe (WE) and Latin America (LA). Design and methods: between January 1, 2011, and December 31, 2013, 1413 TB/HIV patients (62 clinics in 19 countries in EE, WE, Southern Europe (SE), and LA) were enrolled. Results: significant differences were observed between EE (N = 844), WE (N = 152), SE (N = 164), and LA (N = 253) in the proportion of patients with a definite TB diagnosis (47%, 71%, 72% and 40%, p<0.0001), MDR-TB (40%, 5%, 3% and 15%, p<0.0001), and use of combination antiretroviral therapy (cART) (17%, 40%, 44% and 35%, p<0.0001). Injecting drug use (adjusted OR (aOR) = 2.03 (95% CI 1.00-4.09), prior anti-TB treatment (3.42 (1.88-6.22)), and living in EE (7.19 (3.28-15.78)) were associated with MDR-TB. Among 585 patients with drug susceptibility test (DST) results, the empiric (i.e. without knowledge of the DST results) anti-TB treatment included ≥3 active drugs in 66% of participants in EE compared with 90-96% in other regions (p<0.0001). Conclusions: in EE, TB/HIV patients were less likely to receive a definite TB diagnosis, more likely to house MDR-TB and commonly received empiric anti-TB treatment with reduced activity. Improved management of TB/HIV patients in EE requires better access to TB diagnostics including DSTs, empiric anti-TB therapy directed at both susceptible and MDR-TB, and more widespread use of cART.
Note: Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0145380
It is part of: PLoS One, 2015, vol. 10, num. 12, p. e0145380
Related resource: http://dx.doi.org/10.1371/journal.pone.0145380
URI: http://hdl.handle.net/2445/99640
ISSN: 1932-6203
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
662116.pdf871.94 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons